Last reviewed · How we verify
Chlorhexidine, Mupirocin — Competitive Intelligence Brief
marketed
Topical antimicrobial combination
Bacterial cell membrane (chlorhexidine); isoleucyl-tRNA synthetase (mupirocin)
Dermatology / Infection Prevention
Small molecule
Live · refreshed every 30 min
Target snapshot
Chlorhexidine, Mupirocin (Chlorhexidine, Mupirocin) — University of Tennessee. This combination of chlorhexidine and mupirocin works by disrupting bacterial cell membranes and inhibiting bacterial protein synthesis to prevent and treat skin infections.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chlorhexidine, Mupirocin TARGET | Chlorhexidine, Mupirocin | University of Tennessee | marketed | Topical antimicrobial combination | Bacterial cell membrane (chlorhexidine); isoleucyl-tRNA synthetase (mupirocin) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Topical antimicrobial combination class)
- University of Tennessee · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chlorhexidine, Mupirocin CI watch — RSS
- Chlorhexidine, Mupirocin CI watch — Atom
- Chlorhexidine, Mupirocin CI watch — JSON
- Chlorhexidine, Mupirocin alone — RSS
- Whole Topical antimicrobial combination class — RSS
Cite this brief
Drug Landscape (2026). Chlorhexidine, Mupirocin — Competitive Intelligence Brief. https://druglandscape.com/ci/chlorhexidine-mupirocin. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab